TY - JOUR
T1 - Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
AU - Marta, Gustavo Nader
AU - Poortmans, Philip
AU - de Barros, Alfredo C.
AU - Filassi, José Roberto
AU - Freitas Junior, Ruffo
AU - Audisio, Riccardo A.
AU - Mano, Max Senna
AU - Meterissian, Sarkis
AU - DeSnyder, Sarah M.
AU - Buchholz, Thomas A.
AU - Hijal, Tarek
N1 - Publisher Copyright:
© 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
PY - 2017/11
Y1 - 2017/11
N2 - Purpose/Objective(s) Skin sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have entered routine surgical practice for breast cancer, though their oncologic safety has not been established in randomized controlled trials. The aim of this study was to evaluate and compare radiation oncologists' and breast surgeons' opinions concerning the indications of post-operative radiation therapy (PORT) after SSM and NSM. Materials/Methods Radiation oncologists and breast surgeons from North America, South America and Europe were invited to contribute in this study. A 22-question survey was used to evaluate their opinions. Results A total of 550 physicians (298 radiation oncologists and 252 breast surgeons) answered the survey. The majority of responders affirmed that PORT should be performed in early-stage (stages I and II) breast cancer for patients who present with risk factors for relapse after SSM and NSM. They considered age, lymph node involvement, tumor size, extracapsular extension, involved surgical margins, lymphovascular invasion, triple negative receptor status and multicentric presentation as major risk factors. Considering that after SSM and NSM, residual breast tissue can be left behind, the residual tissue considered as acceptable in the context of an oncologic surgery were 1–5 mm for breast surgeons. There is no consensus for the necessity of evaluating residual breast tissue through breast imaging. Conclusion Although the indications of PORT after SSM and NSM vary among practitioners, standard risk factors for relapse are considered as important by radiation oncologists and breast surgeons.
AB - Purpose/Objective(s) Skin sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have entered routine surgical practice for breast cancer, though their oncologic safety has not been established in randomized controlled trials. The aim of this study was to evaluate and compare radiation oncologists' and breast surgeons' opinions concerning the indications of post-operative radiation therapy (PORT) after SSM and NSM. Materials/Methods Radiation oncologists and breast surgeons from North America, South America and Europe were invited to contribute in this study. A 22-question survey was used to evaluate their opinions. Results A total of 550 physicians (298 radiation oncologists and 252 breast surgeons) answered the survey. The majority of responders affirmed that PORT should be performed in early-stage (stages I and II) breast cancer for patients who present with risk factors for relapse after SSM and NSM. They considered age, lymph node involvement, tumor size, extracapsular extension, involved surgical margins, lymphovascular invasion, triple negative receptor status and multicentric presentation as major risk factors. Considering that after SSM and NSM, residual breast tissue can be left behind, the residual tissue considered as acceptable in the context of an oncologic surgery were 1–5 mm for breast surgeons. There is no consensus for the necessity of evaluating residual breast tissue through breast imaging. Conclusion Although the indications of PORT after SSM and NSM vary among practitioners, standard risk factors for relapse are considered as important by radiation oncologists and breast surgeons.
KW - Breast cancer
KW - Nipple-sparing mastectomy
KW - PMRT
KW - Radiation therapy
KW - Skin-sparing mastectomy
UR - http://www.scopus.com/inward/record.url?scp=85030030281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030030281&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2017.09.014
DO - 10.1016/j.ejso.2017.09.014
M3 - Article
C2 - 28967564
AN - SCOPUS:85030030281
SN - 0748-7983
VL - 43
SP - 2036
EP - 2043
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 11
ER -